NOTE: ALL STOCKS IN THIS WATCHLIST ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE CHART. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com).
Stocks highlighted in this watchlist include $ABEO, $HMNY, $MNKD, AMMA
ABEO: Float of 23.57M shares. Oct 6, 2017: Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa. A leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced one-year data from Cohort 1 of the ongoing ABO-102 Phase 1/2 trial for Sanfilippo syndrome Type A (MPS IIIA). The results demonstrated robust and durable clinical effects achieved one-year post-administration, with significant reductions in biopotency and biophysical measures, preservation of deep brain architecture, and stabilization across multiple neurocognitive assessments reported in comparison to untreated control subjects.
HMNY: Float of 3.3M shares with a volume of 14.66M on Tuesday. No pertinent news. IMO, the stock price is moving solely based on built up momentum.
MNKD: Float of 74.72M. On October 2nd, the company announced that the U.S. Food & Drug Administration (FDA) has approved an update to the Afrezza prescribing information to include new clinical data that was presented at the American Diabetes Association's 76th Scientific Sessions in June 2016. Afrezza (insulin human) inhalation powder is approved by the FDA to improve glycemic control in adult patients with type 1 and type 2 diabetes mellitus. It is the only inhaled rapid-acting mealtime insulin available in the United States. Afrezza is dosed at the beginning of a meal and begins to appear in the blood in approximately one minute¹.
Shares of MannKind soared 26% on Tuesday, adding to immense gains recently as analysts expressed optimistic views on the biotech stock. Analysts at H.C. Wainwright opened their coverage of MannKind by giving it a buy rating, setting a $7-per-share price target that helped prompt the latest surge in the stock. The analyst company believes that MannKind's Afrezza inhaled insulin has competitive advantages over injected insulin alternatives, and it expects that MannKind will eventually attract a buyout bid.
AMMA: Float of 9.09M shares. Former MMA judge says AMMA overstated it Operating Margin. In my opinion, the financial statements are correctly stated. In my humble opinion, the former judge is arguing over whether the words "Gross Margin" should have been used instead of "Operating Margin". Regardless of what is used, the financial statements definitely show a big improvement year over year. The comments from this former judge will put AMMA back in the spotlight and likely increase its stock price. Summary of Financials below.